

Lynn Heart and Vascular Institute

Clinical Trials – March 2019

Eugene M. and Christine E. Lynn Office of Research Administration **561.955.4800**

Primary Site	Sponsor/Study ID NCT #	Protocol Description	Eligibility
Thoracoabdominal aneurysm	W. Anthony Lee, MD NCT01524211	Physician-Sponsored IDE: “Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms”	<ul style="list-style-type: none"> • Adult, 18 years and older • Patient must have one of the following: <ul style="list-style-type: none"> ○ Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal aortic aneurysms (fusiform or saccular): ≥ 55 mm in diameter in a male or ≥ 50 mm in diameter in a female, or ○ Thoracoabdominal aortic aneurysm with a history of growth ≥ 0.5 cm per year, or ○ Penetrating ulcers: ≥ 20 mm in depth, or ○ Chronic type B aortic dissections: ≥ 50 mm total aortic diameter, or ○ Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size. • Additional criteria for LP material: Iliofemoral access vessels < 8 mm or with significant atherosclerotic occlusive disease that would require an iliac conduit as determined by the PI.
Infrarenal Abdominal Aortic Aneurysms	Bolton Medical, Inc NCT02009644	IP-0008-12 A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft with Navitel Delivery System for Patients with Infrarenal Abdominal Aortic Aneurysms	<ul style="list-style-type: none"> • Diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement • Must have infrarenal AAA that is ≥ 4.5 cm in diameter for males, or ≥ 4.0 cm in diameter for females, or has increased in diameter by 0.5 cm in the last 6 months
Juxtarenal aortic aneurysms	Cook Incorporated NCT02396199	Evaluation of the safety and effectiveness of the Zenith p-Branch in combination with Atrium iCAST covered stents for the treatment of paraenal or juxtarenal aortic aneurysms.	<ul style="list-style-type: none"> • Pararenal or juxtarenal AAA ≥ 5.0 cm in diameter or 2X normal aortic diameter, or • Pararenal or juxtarenal AAA with history of growth ≥ 0.5 cm/year, or • Saccular aneurysm with aortic diameter $< 1.5X$ normal aortic diameter deemed at risk for rupture by physician
Coronary Bypass	Alexander Kulik, MD NCT02053909	Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency after Coronary Bypass?	<ul style="list-style-type: none"> • Female and/or male aged 18 – 90 years • Undergoing first time CABG with at least 1 saphenous vein graft, irrespective of concurrent valve surgery
	St. Jude Medical, Inc. NCT02832622	MultiPoint Pacing™ Post Market Study (MPP PMS)	<ul style="list-style-type: none"> • Scheduled to receive new CRT implant or upgrade from an existing ICD/Pacemaker implant with no prior LV lead placement